Özge Özkaya, PhD, —
Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.
Articles by Özge Özkaya
Recent Posts
- Cannabidiol gel ZYN002 for fragile X fails to meet goal in clinical trial
- Fragile X, ASD children have distinct brain network patterns
- SPG601 granted orphan drug status in EU for treating fragile X
- Supporters getting ready for Fragile X Awareness Month
- Fragile X treatment KER-0193 gets FDA orphan, rare disease tags
- Long-term ZYN002 eases irritability in fragile X patients: Trial data
- Fragile X treatment KER-0193 found safe in healthy adults in trial
- SPG601 found to reduce measure of abnormal brain activity in fragile X
- SPG601 granted FDA fast track designation for fragile X
- Researchers to study FXTAS risk in people with FMR1 premutation